Novo Nordisk has 'plan B' in place as regulators examine Catalent deal
By Jon Menon ( November 6, 2024, 17:03 GMT | Insight) -- Novo Nordisk says it has a “plan B” in place to scale up production in the event that its parent’s acquisition of US contract drug manufacturer Catalent is blocked by regulators. The Danish drug giant said today that the company expects the deal to close this year, but has an alternative plan should regulators veto the deal.Novo Nordisk says it has a “plan B” in place to scale up production in the event that its parent’s acquisition of US contract drug manufacturer Catalent is blocked by regulators....
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.